13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001802528
Total reported value
$1.5B
$1.5B
15 檔
23.2%
As reported in its official Q1 2025 Form 13F filing, Fairmount Funds Management LLC's tracked investment portfolio stood at $1.5B with 15 total positions.
In Q1 2025, Fairmount Funds Management LLC displayed an active expansion posture, initiating 15 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 14.75% | — | -44.51% | |
| 2 | APGE | Apogee Therapeutics Inc | Stock-Other | 11.87% | +0.80% | — | |
| 3 | SYRE | Spyre Therapeutics Inc | Stock-Other | 10.06% | -14.64% | EXIT | |
| 4 | ELVN | Enliven Therapeutics Inc | Stock-Other | 9.78% | +0.97% | — | |
| 5 | NUVL | Nuvalent Inc-a | Stock-Other | 8.00% | — | -44.78% | |
| 6 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 7.60% | +0.97% | — | |
| 7 | VRDN | Viridian Therapeutics Inc | Stock-Other | 7.21% | +0.65% | — | |
| 8 | SRRK | Scholar Rock Holding CORP | Stock-Other | 6.85% | — | -30.00% | |
| 9 | COGT | Cogent Biosciences Inc | Stock-Other | 5.79% | -1.22% | — | |
| 10 | ORKA | Oruka Therapeutics Inc | Stock-Other | 5.37% | +10.18% | — | |
| 11 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 3.80% | — | -49.77% | |
| 12 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 2.94% | — | — | |
| 13 | ZBIO | Zenas Biopharma Inc | Stock-Other | 2.32% | +0.63% | — | |
| 14 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 2.08% | +0.11% | — | |
| 15 | BCAX | Bicara Therapeutics Inc | Stock-Other | 1.59% | — | -38.94% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | AXSM | Axsome Therapeutics Inc | — | NEW | New buy |
| 2 | APGE | Apogee Therapeutics Inc | — | NEW | New buy |
| 3 | SYRE | Spyre Therapeutics Inc | — | NEW | New buy |
| 4 | ELVN | Enliven Therapeutics Inc | — | NEW | New buy |
| 5 | NUVL | Nuvalent Inc-a | — | NEW | New buy |
| 6 | DNTH | Dianthus Therapeutics Inc | — | NEW | New buy |
| 7 | VRDN | Viridian Therapeutics Inc | — | NEW | New buy |
| 8 | SRRK | Scholar Rock Holding CORP | — | NEW | New buy |
| 9 | COGT | Cogent Biosciences Inc | — | NEW | New buy |
| 10 | ORKA | Oruka Therapeutics Inc | — | NEW | New buy |
| 11 | KNSA | Kiniksa Pharmaceuticals International, plc | — | NEW | New buy |
| 12 | CATBUSD | Astria Therapeutics Inc | — | NEW | New buy |
| 13 | ZBIO | Zenas Biopharma Inc | — | NEW | New buy |
| 14 | IKT | Inhibikase Therapeutics Inc | — | NEW | New buy |
| 15 | BCAX | Bicara Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Fairmount Funds Management LLC reported a total U.S. public equity portfolio value of $1.5B across 15 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including AXSM, APGE, SYRE) accounted for 23.2% of total reported equity market value during Q1 2025.
Top New Position Initiated
AXSM
市值: $95.1M
During Q1 2025, Fairmount Funds Management LLC's top holdings by market value included AXSM (14.8%)、APGE (11.9%)、SYRE (10.1%). The largest single position, AXSM, represented 14.8% of total portfolio value.
In Q1 2025, Fairmount Funds Management LLC made 15 total portfolio adjustments, initiating 15 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.